{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "10508813", "DateCompleted": {"Year": "1999", "Month": "11", "Day": "16"}, "DateRevised": {"Year": "2015", "Month": "11", "Day": "19"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "1073-449X", "JournalIssue": {"Volume": "160", "Issue": "4", "PubDate": {"Year": "1999", "Month": "Oct"}}, "Title": "American journal of respiratory and critical care medicine", "ISOAbbreviation": "Am J Respir Crit Care Med"}, "ArticleTitle": "Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine.", "Pagination": {"StartPage": "1238", "EndPage": "1243", "MedlinePgn": "1238-43"}, "Abstract": {"AbstractText": ["Because chlorofluorocarbons (CFCs) contribute to depletion of stratospheric ozone, CFC-containing metered-dose inhalers (MDIs) such as Ventolin and Proventil are being phased out of production. In terms of delivery of albuterol to the lungs, we compared an alternative delivery system, the Spiros dry-powder inhaler (DPI), with Ventolin, using a methacholine challenge-based clinical bioassay. Twenty-four adults and adolescents with asthma completed this double-blind, four-period crossover study. Doses evaluated were one and three actuations each of Spiros and Ventolin (90- and 270-microgram albuterol base). A methacholine challenge (Cockcroft method) was initiated 3 h before and 0.25 h after albuterol. Predose PC(20)FEV(1) values were not significantly different between study days. Postdose PC(20)FEV(1) results met standard bioassay study validity criteria: i.e., a significant dose-response relationship was present (p = 0.0002); tests for deviation from parallelism and overlap of dose-response curves were nonsignificant (p = 0.08, 0.69). By using Finney 2-by-2 bioassay analysis, we estimate that each Spiros actuation delivers 1.12 times as much albuterol to the airways as one Ventolin actuation (90% confidence interval, 0.68 to 1.94). There were no significant differences in markers of systemic effects (vital signs, potassium, and blood glucose concentrations). We conclude that Spiros and Ventolin inhalers deliver comparable quantities of albuterol to the airways."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Medicine, University of Iowa, Iowa City, Iowa, USA."}], "Identifier": [], "LastName": "Ahrens", "ForeName": "R C", "Initials": "RC"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hendeles", "ForeName": "L", "Initials": "L"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Clarke", "ForeName": "W R", "Initials": "WR"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Dockhorn", "ForeName": "R J", "Initials": "RJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hill", "ForeName": "M R", "Initials": "MR"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Vaughan", "ForeName": "L M", "Initials": "LM"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Lux", "ForeName": "C", "Initials": "C"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Han", "ForeName": "S H", "Initials": "SH"}], "PublicationTypeList": ["Clinical Trial", "Comparative Study", "Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Am J Respir Crit Care Med", "NlmUniqueID": "9421642", "ISSNLinking": "1073-449X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Adrenergic beta-Agonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Bronchoconstrictor Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Bronchodilator Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Powders"}, {"RegistryNumber": "0W5ETF9M2K", "NameOfSubstance": "Methacholine Chloride"}, {"RegistryNumber": "QF8SVZ843E", "NameOfSubstance": "Albuterol"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Adrenergic beta-Agonists"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Albuterol"}, {"QualifierName": ["drug therapy", "physiopathology"], "DescriptorName": "Asthma"}, {"QualifierName": [], "DescriptorName": "Bronchial Provocation Tests"}, {"QualifierName": [], "DescriptorName": "Bronchoconstrictor Agents"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Bronchodilator Agents"}, {"QualifierName": [], "DescriptorName": "Child"}, {"QualifierName": [], "DescriptorName": "Cross-Over Studies"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Methacholine Chloride"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": [], "DescriptorName": "Nebulizers and Vaporizers"}, {"QualifierName": [], "DescriptorName": "Powders"}, {"QualifierName": [], "DescriptorName": "Therapeutic Equivalency"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1999", "Month": "10", "Day": "6"}, {"Year": "1999", "Month": "10", "Day": "6", "Hour": "0", "Minute": "1"}, {"Year": "1999", "Month": "10", "Day": "6", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["10508813", "10.1164/ajrccm.160.4.9806101"]}}], "PubmedBookArticle": []}